JP2017532959A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532959A5
JP2017532959A5 JP2017519013A JP2017519013A JP2017532959A5 JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5 JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5
Authority
JP
Japan
Prior art keywords
subject
gene
threshold
mdm2i
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/079389 external-priority patent/WO2016056673A1/en
Publication of JP2017532959A publication Critical patent/JP2017532959A/ja
Publication of JP2017532959A5 publication Critical patent/JP2017532959A5/ja
Withdrawn legal-status Critical Current

Links

JP2017519013A 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム Withdrawn JP2017532959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061992P 2014-10-09 2014-10-09
US62/061,992 2014-10-09
PCT/JP2015/079389 WO2016056673A1 (en) 2014-10-09 2015-10-09 Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017532959A JP2017532959A (ja) 2017-11-09
JP2017532959A5 true JP2017532959A5 (enExample) 2018-11-22

Family

ID=54396934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519013A Withdrawn JP2017532959A (ja) 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム

Country Status (4)

Country Link
US (1) US20170283885A1 (enExample)
EP (1) EP3204514A1 (enExample)
JP (1) JP2017532959A (enExample)
WO (1) WO2016056673A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
CN107974502B (zh) * 2016-10-19 2021-07-02 北京大学人民医院 一种用于同时检测nbpf10、tsfm、prb2及diaph1基因突变的试剂盒
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021228814A1 (en) * 2020-05-15 2021-11-18 ETH Zürich Mdm2 inhibitor response prediction method
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023009174A1 (en) * 2021-07-30 2023-02-02 Oregon Health & Science University Methods for predicting lymph node status, likelihood of metastasis, and/or overall prognosis in patients with melanoma
CN118398086B (zh) * 2024-04-19 2026-01-06 山东云海国创云计算装备产业创新中心有限公司 抗癌药物反应预测方法、装置、计算机设备及存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2463820T3 (es) * 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Derivado de imidazotiazol que tiene estructura de anillo de prolina
BR112013023175B1 (pt) * 2011-03-10 2022-11-16 Daiichi Sankyo Company, Limited Composto, composição farmacêutica, e, uso do composto
US20120328692A1 (en) * 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
US20150159222A1 (en) * 2012-07-31 2015-06-11 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2014065760A1 (en) * 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
SG11201510816SA (en) * 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Similar Documents

Publication Publication Date Title
JP2017532959A5 (enExample)
Paulsen et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability
Westphal et al. Circulating biomarkers for gliomas
JP2017508442A5 (enExample)
Carini et al. Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Arimappamagan et al. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group
JP2010518811A5 (enExample)
Anaka et al. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
Yuan et al. Identification of a Nine Immune‐Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma
Liu et al. A single-cell transcriptional landscape of immune cells shows disease-specific changes of T cell and macrophage populations in human achalasia
Zhang et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma
Xie et al. An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy
JP2022522354A (ja) 肝がん再発予測用dnaメチル化マーカー及びその用途
Yu et al. Genome-wide analysis of genetic variations assisted by Ingenuity Pathway Analysis to comprehensively investigate potential genetic targets associated with the progression of hepatocellular carcinoma
Cruz‐Granados et al. Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease
Qu et al. Comprehensive analysis of the correlation between pyroptosis-related LncRNAs and tumor microenvironment, prognosis, and immune infiltration in hepatocellular carcinoma
JP2018538247A5 (enExample)
Niu et al. Integrative Disulfidptosis‐Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma
Wei et al. Identification and validation of IFI44 as a novel biomarker for primary Sjögren’s syndrome
Lu et al. Dysregulation of TFDP1 and of the cell cycle pathway in high-grade glioblastoma multiforme: a bioinformatic analysis
Cho et al. Involvement of DDX6 gene in radio-and chemoresistance in glioblastoma
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
Yang et al. Construction of cuproptosis‑associated prognostic signature in colon adenocarcinoma based on bioinformatics and RT‑qPCR analysis
van Persie et al. Complete genome sequence of a novel chimpanzee polyomavirus from a western common chimpanzee
Pan et al. Identification of Cbx6 as a potential biomarker in renal ischemia/reperfusion injury